This company has been marked as potentially delisted and may not be actively trading. Oasmia Pharmaceutical AB (publ) (OASM) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OASM vs. ATNF, NLSP, APLM, MYNZ, MTVA, GTBP, APM, AEON, SILO, and ENSCShould you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include 180 Life Sciences (ATNF), NLS Pharmaceutics (NLSP), Apollomics (APLM), Mainz Biomed (MYNZ), MetaVia (MTVA), GT Biopharma (GTBP), Aptorum Group (APM), AEON Biopharma (AEON), Silo Pharma (SILO), and Ensysce Biosciences (ENSC). These companies are all part of the "medical" sector. Oasmia Pharmaceutical AB (publ) vs. 180 Life Sciences NLS Pharmaceutics Apollomics Mainz Biomed MetaVia GT Biopharma Aptorum Group AEON Biopharma Silo Pharma Ensysce Biosciences 180 Life Sciences (NASDAQ:ATNF) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation. Which has preferable earnings & valuation, ATNF or OASM? Oasmia Pharmaceutical AB (publ) has higher revenue and earnings than 180 Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$19.93MN/AN/AOasmia Pharmaceutical AB (publ)$220K6.82-$18.95MN/AN/A Which has more volatility & risk, ATNF or OASM? 180 Life Sciences has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Does the media prefer ATNF or OASM? In the previous week, 180 Life Sciences had 1 more articles in the media than Oasmia Pharmaceutical AB (publ). MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Oasmia Pharmaceutical AB (publ). 180 Life Sciences' average media sentiment score of 1.38 beat Oasmia Pharmaceutical AB (publ)'s score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Positive Oasmia Pharmaceutical AB (publ) Neutral Is ATNF or OASM more profitable? 180 Life Sciences has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -558.93% -54.10% Oasmia Pharmaceutical AB (publ) -8,633.64%-43.94%-28.92% Does the MarketBeat Community prefer ATNF or OASM? Oasmia Pharmaceutical AB (publ) received 124 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 65.97% of users gave Oasmia Pharmaceutical AB (publ) an outperform vote while only 16.67% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperform180 Life SciencesOutperform Votes216.67%Underperform Votes1083.33% Oasmia Pharmaceutical AB (publ)Outperform Votes12665.97% Underperform Votes6534.03% Do institutionals and insiders hold more shares of ATNF or OASM? 4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. 0.2% of 180 Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryOasmia Pharmaceutical AB (publ) beats 180 Life Sciences on 7 of the 12 factors compared between the two stocks. Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OASM vs. The Competition Export to ExcelMetricOasmia Pharmaceutical AB (publ)Pharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E RatioN/A8.9226.7619.71Price / Sales6.82252.24389.94117.54Price / CashN/A65.8538.2534.62Price / Book0.036.466.804.50Net Income-$18.95M$143.98M$3.23B$248.18M Oasmia Pharmaceutical AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OASMOasmia Pharmaceutical AB (publ)N/A$0.02flatN/AN/A$1.50M$220,000.000.0057ATNF180 Life SciencesN/A$1.15+4.5%N/A-47.2%$5.96MN/A0.007Earnings ReportNLSPNLS PharmaceuticsN/A$1.63-0.6%N/A+1,024.2%$5.87MN/A0.006News CoveragePositive NewsGap UpAPLMApollomicsN/A$5.20+1.2%N/A-78.7%$5.74M$1.22M0.0045MYNZMainz Biomed2.2756 of 5 stars$2.47-2.8%$14.00+466.8%-91.0%$5.73M$893,991.00-0.0430Gap DownMTVAMetaVia1.8101 of 5 stars$0.65-7.2%$12.00+1,746.2%N/A$5.63MN/A0.008News CoverageAnalyst ForecastGTBPGT Biopharma2.9582 of 5 stars$2.18-5.2%$11.00+404.6%-52.5%$5.53MN/A-0.318Earnings ReportGap DownAPMAptorum Group0.3453 of 5 stars$0.99+6.7%N/A-76.6%$5.30M$430,000.000.0030Positive NewsGap DownAEONAEON Biopharma2.3268 of 5 stars$0.50+2.1%$360.00+71,584.6%-99.6%$5.29MN/A2.795News CoverageSILOSilo Pharma0.3334 of 5 stars$1.10+2.8%N/A-79.6%$4.93M$72,102.00-0.942News CoverageENSCEnsysce Biosciences0.2294 of 5 stars$2.07-5.5%N/A-78.1%$4.91M$2.23M-0.0810Gap Down Related Companies and Tools Related Companies ATNF Competitors NLSP Competitors APLM Competitors MYNZ Competitors MTVA Competitors GTBP Competitors APM Competitors AEON Competitors SILO Competitors ENSC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OASM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
